Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $63.50.

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a report on Monday, September 9th. Guggenheim reiterated a “buy” rating on shares of Arvinas in a research report on Thursday, December 12th. Stephens started coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. BMO Capital Markets lowered their price target on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Finally, BTIG Research assumed coverage on shares of Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price target on the stock.

Institutional Trading of Arvinas

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its holdings in shares of Arvinas by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after acquiring an additional 367,343 shares during the period. Franklin Resources Inc. grew its stake in Arvinas by 11.6% in the third quarter. Franklin Resources Inc. now owns 69,190 shares of the company’s stock worth $1,776,000 after purchasing an additional 7,166 shares during the period. M&T Bank Corp raised its holdings in Arvinas by 53.5% in the third quarter. M&T Bank Corp now owns 27,137 shares of the company’s stock worth $669,000 after purchasing an additional 9,462 shares in the last quarter. Barclays PLC lifted its position in Arvinas by 198.9% during the third quarter. Barclays PLC now owns 121,699 shares of the company’s stock valued at $2,998,000 after buying an additional 80,984 shares during the period. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in shares of Arvinas by 36.3% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 90,870 shares of the company’s stock valued at $2,238,000 after buying an additional 24,223 shares in the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Price Performance

Shares of NASDAQ ARVN opened at $18.89 on Friday. The stock has a market capitalization of $1.30 billion, a P/E ratio of -4.04 and a beta of 1.82. Arvinas has a one year low of $17.37 and a one year high of $53.08. The firm’s 50 day simple moving average is $23.44 and its two-hundred day simple moving average is $25.08.

Arvinas (NASDAQ:ARVN) last released its earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to the consensus estimate of $60.56 million. Arvinas’s revenue for the quarter was up 196.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.18) EPS. As a group, equities analysts expect that Arvinas will post -3.22 earnings per share for the current fiscal year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.